$5.67
2.16% yesterday
Nasdaq, Sep 27, 10:00 pm CET
ISIN
US7611234052
Symbol
RSLS

ReShape Lifesciences, Inc. Stock price

$5.67
-4.08 41.85% 1M
-4.84 46.05% 6M
-8.81 60.85% YTD
-24.49 81.20% 1Y
-8,404.33 99.93% 3Y
-17,655.33 99.97% 5Y
-325,457,994.33 100.00% 10Y
Nasdaq, Closing price Fri, Sep 27 2024
+0.12 2.16%
ISIN
US7611234052
Symbol
RSLS
Sector

Key metrics

Market capitalization $2.81m
Enterprise Value $1.88m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 0.23
P/S ratio (TTM) P/S ratio 0.35
P/B ratio (TTM) P/B ratio 0.93
Revenue growth (TTM) Revenue growth -23.00%
Revenue (TTM) Revenue $8.05m
EBIT (operating result TTM) EBIT $-9.26m
Free Cash Flow (TTM) Free Cash Flow $-8.67m
Cash position $1.15m
EPS (TTM) EPS $-72.66
P/E forward negative
P/S forward 0.44
EV/Sales forward 0.32
Short interest 2.14%
Show more

Is ReShape Lifesciences, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

ReShape Lifesciences, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast ReShape Lifesciences, Inc.:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast ReShape Lifesciences, Inc.:

Buy
100%

Financial data from ReShape Lifesciences, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
8.05 8.05
23% 23%
100%
- Direct Costs 2.62 2.62
39% 39%
33%
5.43 5.43
11% 11%
67%
- Selling and Administrative Expenses 12 12
44% 44%
155%
- Research and Development Expense 2.16 2.16
5% 5%
27%
-9.19 -9.19
49% 49%
-114%
- Depreciation and Amortization 0.07 0.07
94% 94%
1%
EBIT (Operating Income) EBIT -9.26 -9.26
52% 52%
-115%
Net Profit -9.02 -9.02
74% 74%
-112%

In millions USD.

Don't miss a Thing! We will send you all news about ReShape Lifesciences, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ReShape Lifesciences, Inc. Stock News

Neutral
GlobeNewsWire
8 days ago
IRVINE, Calif., Sept. 19, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that its Board of Directors has declared a 1-for-58 reverse stock split of the company's common stock, which will be effective for trading purposes upon the commencement of trading on September 23, 2024.
Neutral
Seeking Alpha
about one month ago
ReShape Lifesciences Inc. (NASDAQ:RSLS ) Q2 2024 Earnings Conference Call August 15, 2024 4:30 PM ET Company Participants Michael Miller - IR Paul Hickey - President and CEO Thomas Stankovich - CFO Krishna Gupta - Director, Vyome Therapeutics Conference Call Participants Operator Good day, and thank you for standing by. Welcome to the ReShape Lifesciences Second Quarter 2024 Earnings Call.
Neutral
GlobeNewsWire
about 2 months ago
Conference Call to be Held at 4:30 pm ET on Thursday, August 15, 2024 Conference Call to be Held at 4:30 pm ET on Thursday, August 15, 2024
More ReShape Lifesciences, Inc. News

Company Profile

ReShape Lifesciences Inc. operates as a medical device company, which focuses on technology to treat obesity and metabolic diseases. It operates through the following segments: Lap-Band, ReShape Vest and ReShape vBloc. The company was founded on December 2002 and is headquartered in San Clemente, CA.

Head office United States
CEO Paul Hickey
Employees 31
Founded 2002
Website www.reshapelifesciences.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today